11 · Pattern recognition

Pattern recognition

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Pattern recognition across your briefs

Pan-RAS drugs move toward first line. Revolution’s chemotherapy combination and Erasca’s monotherapy both report pancreatic cancer responses this week, and both companies point to first-line Phase 3 trials. Neither result is randomized. Analysis

Tuberculosis regimens. NEJM’s PARADIGM4TB and BioVersys’s ENABLE both test new drug combinations against standard treatment; only the NEJM trial gives numbers. Analysis

Complement in myasthenia gravis. Livsayis follows Klygefa, which FDA lists as approved for the disease on 11.13; two approvals in a week give patients more dosing choices, not a new mechanism. Analysis